, Tracking Stock Market Picks
Enter Symbol:
Impax Laboratories, Inc. (IPXL) [hlAlert]

up 52.99 %

Impax Laboratories, Inc. (IPXL) rated Buy with price target $30 by WallachBeth

Posted on: Friday,  Oct 10, 2014  8:25 AM ET by WallachBeth

WallachBeth rated Buy Impax Laboratories, Inc. (NASDAQ: IPXL) on 10/10/2014. Previously WallachBeth rated Buy Impax Laboratories, Inc. (NASDAQ: IPXL) on 06/06/2014.,
when the stock price was $28.74. Since then, Impax Laboratories, Inc. has gained 52.99% as of 01/20/2016's recent price of $43.97.
If you would have followed the previous WallachBeth's recommendation on IPXL, you would have gained 52.99% of your investment in 593 days.

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. In the generic pharmaceuticals market, the Company focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system (CNS), disorders. Its brand-name product portfolio consists of development-stage projects to which it is applying its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceutical Division (Impax Division).

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/10/2014 8:25 AM Buy
26.88 30.00
as of 10/17/2014
1 Week down  -1.94 %
1 Month up  7.87 %
3 Months down  -3.64 %
1 YTD down  -0.63 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/6/2014 12:00 AM Buy
28.74 32.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy